Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;42(3):1203-1214.
doi: 10.3892/ijmm.2018.3744. Epub 2018 Jun 26.

Prostaglandin EP2 Receptor: Novel Therapeutic Target for Human Cancers (Review)

Affiliations
Review

Prostaglandin EP2 Receptor: Novel Therapeutic Target for Human Cancers (Review)

Xiaoting Sun et al. Int J Mol Med. .

Abstract

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein‑coupled receptor, PGE2‑induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3β and β‑catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms

Substances

LinkOut - more resources

Feedback